Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Veltuzumab and 90Y-Epratuzumab in Follicular Lymphoma
NCT01147393Phase 2Terminated
- Sponsor
- Weill Cornell Medicine
- Start
- Oct 2010
- Primary completion
- Aug 2013
- Modality
- IgG Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of 90Y-epratuzumab tetraxetan, veltuzumab in follicular lymphoma (FL), sponsored by Weill Cornell Medicine. Started Oct 2010; status: terminated.
02
Drugs
90Y-epratuzumab tetraxetanveltuzumab
03
Conditions
follicular lymphoma (FL)
Beyond the preview
Go deeper on NCT01147393.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01147393.